266369-49-7

Usage

Uses

Used in Chemical Research:
4-(1,3-Thiazol-2-yl)benzoic acid is used as a research compound for exploring its chemical properties and potential interactions with other molecules. Its unique structure, combining a thiazole ring with benzoic acid, makes it an interesting subject for studies in synthetic chemistry and material science.
Used in Pharmaceutical Formulations:
Although specific biological activity is not well-documented, 4-(1,3-thiazol-2-yl)benzoic acid is used as a potential pharmaceutical intermediate. Its carboxylic acid functional group could be exploited in the development of new drugs, particularly in the context of its potential anti-inflammatory, antibacterial, or antifungal properties.
Used in Material Science:
4-(1,3-Thiazol-2-yl)benzoic acid is used as a component in the development of new materials, where its chemical properties may contribute to the creation of novel compounds with specific characteristics, such as improved stability or reactivity in various applications.

InChI:InChI=1/C10H7NO2S/c12-10(13)8-3-1-7(2-4-8)9-11-5-6-14-9/h1-6H,(H,12,13)

Upstream product

• 7758-19-2 sodium chlorite 
• 10049-21-5 sodium dihydrogenphosphate 
• 513-35-9 2-methyl-but-2-ene 
• 198904-53-9 4-(thiazol-2-yl)-benzaldehyde 
• 5798-75-4 Ethyl 4-bromobenzoate 
• 257876-04-3 4-thiazol-2-yl-benzoic acid ethyl ester 
• 40881-45-6 4-tolylboronic dimethyl ester 
• 3034-53-5 2-bromo-1,3-thiazole 
• 14047-29-1 4-carboxyphenylboronic acid 
• 5720-05-8 4-methylphenylboronic acid 
• 106-38-7 para-bromotoluene 

Relevant academic research and scientific papers

Organic Solvent-Free, Pd(II)-Salan Complex-Catalyzed Synthesis of Biaryls via Suzuki-Miyaura Cross-Coupling in Water and Air

With use of a Pd(II)-sulfosalan complex as a water-soluble catalyst, we have developed an efficient synthesis of biaryls via Suzuki-Miyaura cross-coupling in water under aerobic conditions. The water-insoluble target molecules were isolated by simple filtration in analytical purity after washing with 0.01 M aqueous HCl (20 examples). In most cases, palladium contamination was below 5 ppm considered acceptable for active pharmaceutical ingredients. The established method is scalable, reproducible, and provides biaryl products in isolated yields up to 91%.

Preparation method of (5-halogenothiazole-2-yl) benzoic acid compounds

The invention discloses a preparation method of (5-halogenothiazole-2-yl) benzoic acid compounds. The method comprises the steps of firstly synthesizing thiazole benzoate compounds by taking 2-bromine thiazole as a raw material, then halogenating and hydr

Zinc Coordination Polymers Containing Isomeric Forms of p-(Thiazolyl)benzoic Acid: Blue-Emitting Materials with a Solvatochromic Response to Water

Two coordination polymers of assorted dimensionality (1D, 2D) have been prepared, namely [Zn3(L2Th)4(OH)2·2(HL2Th)]∞ (1) and [Zn(L5Th)(OAc)]∞ (2), starting from ZnII salts and the isomeric forms of the organic linker p-(thiazolyl)benzoic acid: p-(2-thiazolyl)benzoic acid (HL2Th) and p-(5-thiazolyl)benzoic acid (HL5Th). The isomers have been prepared ad hoc, following straightforward Pd-catalyzed C–C coupling reaction protocols. In 1, the deprotonated ligand is coordinated through its carboxylate group only, with dangling thiazole groups. The –COO– units are bridging adjacent metal centers, thus creating a 1D chain. The Zn3 cluster is made of one six-coordinate (Oh) and two four-coordinate (Td) ZnII ions; triple-bridging μ3-OH groups are balancing the overall positive charge. The structure of 2 is instead made of Zn2(carboxylate)4 “paddle-wheel” dimers as the constituting inorganic node. The octahedral metal coordination sphere includes two μ-(κ-COO) benzoate spacers, two μ-(κ-COO) acetate ions, the thiazole N atoms coming from adjacent building blocks, and a weak Zn···Zn axial interaction. The resulting final assembly is two-dimensional (2D), where p-(5-thiazolyl)benzoate adopts a genuine μ-[κ(COO):κ(N)] bridging coordination mode. The luminescent properties of both polymers have been analyzed in the solid state; they feature ligand-centered emissions at λ = 434 nm (1) and λ = 427 nm (2). These electronic transitions fall in the visible region, giving the samples a characteristic blue color under an ordinary UV lamp (excitation at λ = 254 nm). The theoretical analysis of the electronic features of the ligands and related molecular orbitals reveals that the observed transitions are mainly of π→π* nature, involving π orbitals delocalized on both aromatic cycles. A significant (reversible) blueshift of the emission maximum of ca. 60 nm, from the visible to the UV region, has been observed for 1 when suspended in water.

A Arylheterocycle chirality bcr - abl inhibitor and its preparation method and application

The invention discloses aromatic heterocyclic biphenyl Bcr-Abl inhibitors as well as a preparation method and application thereof. A structural formula of the inhibitors is shown in the specification, wherein in the structural formula, Ar is aromatic heterocycle; R is a mono-substituent or a di-substituent, and the substituent is alkyl or halogen. The series of inhibitors have a certain inhibiting effect on ABL1 kinase in vitro, can inhibit tumor cell proliferation and can be used for preparing antitumor drugs, especially CML (chronic myelocytic leukemia) drugs. The preparation method of the aromatic heterocyclic biphenyl Bcr-Abl inhibitors, which is provided by the invention, has the advantages of easiness in obtainment of raw materials, mild reaction conditions, simplicity in operation of reaction processes and cheap used reagents.

Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents

As a continuation to our previous research, twenty-eight aromatic-heterocyclic biphenyls were designed and synthesized as novel Bcr-Abl inhibitors. The title compounds were investigated for their antiproliferative activities against wild K562 cells and Imatinib-resistant K562 cells (K562R). The results indicated that most of them exhibited potent Bcr-Abl inhibition and moderate antiproliferative potency against K562 cells. Furthermore, three compounds 3, 7 and 21 displayed moderate antiproliferative activities against K562R cells. Molecular docking indicated that 3 bound more tightly with Bcr-AblT315I compared to Bcr-AblWT. The higher affinity was consistent with its relatively promising K562R cell growth inhibition. These aromatic-heterocyclic biphenyls could be considered as novel lead compound for optimized as Bcr-AblT315I inhibitors. They provide a good starting point for the further development of novel anti-leukemia agents capable of dealing with clinical acquired resistance against Imatinib.

Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists

This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2).

FIBROSIS INHIBITOR

Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2):(1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms:(2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.

Pyrrole derivatives

Pyrrole derivatives represented by the following formula: wherein Ring Z is an optionally substituted pyrrole ring, etc.; W2 is —CO—, —SO2—, an optionally substituted C1-C4 alkylene, etc.; Ar2 is an optionally substituted aryl, etc.; W2 and Ar1 mean the following (1) and (2): (1) W1 is an optionally substituted C1-C4 alkylene, etc.; Ar1 is an optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is an optionally substituted C2-C5 alkylene, an optionally substituted C2-C5 alkenylene, etc.; and Ar1 is an aryl or monocyclic heteroaryl, which are substituted by carboxyl, an alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof These compounds are useful as medicaments such as a fibrosis inhibitor for organs or tissues.

COMPOUNDS AND METHODS

This invention relates to substituted heteroanilide compounds which are modulators, agonists or antagonists, of the CCR5 receptior. In addition, this invention relates to the treatment and prevention of disease states mediatd by CCR5.

AROMATIC AMINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND AGENTS CONTAINING THE SAME

Compounds of a formula: wherein Ring A represents an optionally-substituted aromatic ring; Ring B represents an optionally-substituted cyclic hydrocarbon group; Z represents an optionally-substituted cyclic group; R1 represents a hydrogen atom, an optionally-substituted hydrocarbon group, an optionally-substituted heterocyclic group, or an acyl group; R2 represents an optionally-substituted amino group; D represents a chemical bond or a divalent group; E represents -CO-, -CON(Ra)-, COO-, -N(Ra)CON(Rb)-, -N(Ra)COO-, -N(Ra)SO2-, -N(Ra)-, -O-, -S-,-SO- or -SO2- (in which Ra and Rb each independently represent a hydrogen atom or an optionally-substituted hydrocarbon group); G represents a chemical bond or a divalent group; L represents (1) a chemical bond or (2) a divalent hydrocarbon group optionally having from 1 to 5 substituents selected from;(i) a C1-6 alkyl group,(ii) a halogeno-C1-6 alkyl group,(iii) a phenyl group,(iv) a benzyl group,(v) an optionally-substituted amino group,(vi) an optionally-substituted hydroxy group, and(vii) a carbamoyl or thiocarbamoyl group optionally substituted by: a C1-6 alkyl group, an optionally-substituted phenyl group, or an optionally-substituted heterocyclic group, and optionally interrupted by -O- or -S-; X represents an oxygen atom, an optionally-oxidized sulfur atom, an optionally-substituted nitrogen atom, or an optionally-substituted divalent hydrocarbon group; Y represents two hydrogen atoms, an oxygen atom or a sulfur atom; .... means that R2 may be bonded to the atom on Ring B to form a ring, or their salts, and a method for producing them.